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Head and Neck Cancer Surgery During the COVID-19 Pandemic: 
An International, Multicenter, Observational Cohort Study
COVIDSurg Collaborative
BACKGROUND: The aims of this study were to provide data on the safety of head and neck cancer surgery currently being undertaken 
during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: This international, observational cohort study comprised 1137 
consecutive patients with head and neck cancer undergoing primary surgery with curative intent in 26 countries. Factors associated 
with severe pulmonary complications in COVID-19–positive patients and infections in the surgical team were determined by univariate 
analysis. RESULTS: Among the 1137 patients, the commonest sites were the oral cavity (38%) and the thyroid (21%). For oropharynx 
and larynx tumors, nonsurgical therapy was favored in most cases. There was evidence of surgical de-escalation of neck management 
and reconstruction. Overall 30-day mortality was 1.2%. Twenty-nine patients (3%) tested positive for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) within 30 days of surgery; 13 of these patients (44.8%) developed severe respiratory complications, and 3.51 
(10.3%) died. There were significant correlations with an advanced tumor stage and admission to critical care. Members of the surgical 
team tested positive within 30 days of surgery in 40 cases (3%). There were significant associations with operations in which the patients 
also tested positive for SARS-CoV-2 within 30 days, with a high community incidence of SARS-CoV-2, with screened patients, with oral 
tumor sites, and with tracheostomy. CONCLUSIONS: Head and neck cancer surgery in the COVID-19 era appears safe even when surgery 
is prolonged and complex. The overlap in COVID-19 between patients and members of the surgical team raises the suspicion of failures 
in cross-infection measures or the use of personal protective equipment. Cancer 2020;0:1-13. © 2020 American Cancer Society This is 
an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited. 
LAY SUMMARY: 
• Head and neck surgery is safe for patients during the coronavirus disease 2019 pandemic even when it is lengthy and complex.
• This is significant because concerns over patient safety raised in many guidelines appear not to be reflected by outcomes, even for 
those who have other serious illnesses or require complex reconstructions.
• Patients subjected to suboptimal or nonstandard treatments should be carefully followed up to optimize their cancer outcomes.
• The overlap between patients and surgeons testing positive for severe acute respiratory syndrome coronavirus 2 is notable and em-
phasizes the need for fastidious cross-infection controls and effective personal protective equipment. 
KEYWORDS: coronavirus, coronavirus disease 2019 (COVID-19), head and neck cancer, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), surgery.
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) coronavirus infection, has led to a rapid reduction of elective surgery due to a lack of capacity and con-
cerns over patient safety.1 The problems are highlighted in surgical oncology, where a delay or cancellation of surgery may 
directly lead to poor outcomes or, at worst, increased loss of life. Recent international data from 1128 patients known 
to be suffering from COVID-19 at the time of surgery showed a severe pulmonary complication rate of 51.2% and a 
mortality rate of 23.8%.2 Surgeons operating in the upper aerodigestive tract are at particularly high risk of contracting 
COVID-19, with many severe cases and some fatalities reported.3-5
In head and neck cancer surgery, published guidelines for the COVID-19 pandemic3,5-21 have been formulated on 
the basis of reasonable assumptions, experience from severe acute respiratory syndrome (SARS),7 and consensus reached 
with the Delphi method16 rather than patient-level data. For squamous cell carcinomas (SCCs) of the oropharynx (OP) 
and larynx (L), there is equipoise between the effectiveness of primary surgery and (chemo)radiotherapy; avoiding surgery 
has been recommended. A delay of surgery appears pragmatic for more indolent thyroid malignancies. For other head and 
neck tumors such as oral cavity (OC) SCCs and salivary gland malignancies, it is of considerable importance that nonsur-
gical management is frequently suboptimal, and considerable dilemmas remain. New guidelines have recommended the 
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avoidance of procedures presumed to be high-risk, such as 
tracheostomy and free-flap reconstruction, and de-escala-
tion to palliative treatment for the elderly or those with a 
poor performance status.16
Typically, SCCs of the head and neck have a short 
tumor volume doubling time,22 so delays in diagnosis and 
treatment engender a high risk of upstaging. Surgery can 
be prolonged, can involve direct airway manipulations 
and aerosol-generating procedures, and can necessitate 
complex reconstruction such as microvascular free tissue 
transfer. Routine reliance on critical care for postoperative 
recovery is common to many institutions, and this may 
increase the risk of cross-infection with the SARS-CoV-2 
virus. However, in oral SCCs, salivary malignancies, and 
other such cases, the opportunities for a cure are reliant 
on surgery, and without evidence-based alternative mo-
dalities, the imperative is to schedule surgery without 
delay. Anecdotally, the perceived risk of uncontrolled 
locoregional disease in patients with advanced SCC of 
the head and neck has led many services to preserve head 
and neck oncology despite the huge resource constraint, 
whereas most other oncology services have been paused.
Among these pragmatic assumptions, there is a 
paucity of data to inform practice. Tangible opportu-
nities exist to capture real-world data that might affect 
cancer surgery through the COVID-19 pandemic itera-
tively and with immediate effect. With this rationale, the 
Global Health Research Unit of the National Institute 
for Health Research launched COVIDSurg for oncology 
(https://globa lsurg.org/covid surg/), with head and neck 
cancer–specific fields incorporated early in its evolution 
and with an international collaborative group designing 
it. The objective of this first output for the head and 
neck data from COVIDSurg is to describe surgical prac-
tice and safety during the early period of the pandemic.
The aims are 1) to describe the range of surgeries 
performed within the first 3 months of the pandemic 
and to estimate the extent of therapeutic migration and 
surgical de-escalation by comparison with historical 
data, 2) to determine patient safety regarding 30-day 
outcomes for mortality and severe pulmonary compli-
cations attributable to COVID-19, and 3) to determine 
the 30-day incidence of COVID-19 in the surgical team.
MATERIALS AND METHODS
Design
This international, observational cohort study included 
patients with a diagnosis of head and neck malignancy 
who underwent primary surgery with curative intent 
during the COVID-19 pandemic. Only routine, an-
onymized data were collected, and ethics and data release 
were managed though an ethics committee and an inde-
pendent data monitoring committee. The study was reg-
istered at each site as either a clinical audit or a service 
evaluation; this reflected that the regulatory permissions 
required varied from country to country.
Inclusion Criteria
Patients were eligible for study inclusion from the date 
of that hospital’s first admission of an individual testing 
positive for a SARS-CoV-2 infection up to 3 months 
from that date or the data lock on June 17, 2020, which-
ever came first. Each participating hospital included 
consecutive adult patients undergoing head and neck 
cancer surgery with curative intent. Surgery was defined 
as a procedure performed by a surgeon in an operating 
theater under general or local anesthesia. Head and neck 
cancer was defined as any malignant diagnosis above 
the clavicle excluding localized nonmelanoma skin, 
hematopoietic, intra-ocular, and primary brain malig-
nancies. The study was publicized globally through the 
International Federation of Head and Neck Oncological 
Societies, the International Academy of Oral Oncology, 
the European Association of Craniomaxillofacial 
Surgery, and other national associations.
Outcome Measures
Outcome measures were mortality, complications, and 
a SARS-CoV-2 infection within 30 days of surgery. 
Specifically, the primary measure of interest for patient 
safety was the diagnosis of severe pulmonary complica-
tions with either a positive SARS-CoV-2 diagnosis or a 
clinical diagnosis of COVID-19. Secondary outcome 
measures included the TNM stage, tumor subsite, his-
tology, and specific ablative and reconstructive surgery 
undertaken to evaluate the impact of the COVID-19 
pandemic on case selection and treatment pathways. The 
diagnosis of a SARS-CoV-2 infection within 30 days of 
the operation in any member of the operating team was 
also recorded.
Diagnosis of SARS-CoV-2 Infection
Laboratory testing for SARS-CoV-2 infection was based on 
viral RNA detection by quantitative reverse transcription–
polymerase chain reaction. Sampling, including nasal swabs 
and/or bronchoalveolar lavage, and analyses were performed 
according to local hospital protocols. Because quantitative 
reverse transcription–polymerase chain reaction testing was 
not available at all participating hospitals at all times, patients 
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were also included on the basis of alternative laboratory tests 
or clinical or radiological findings. This was done by a sen-
ior physician and was based on the clinical presentation of 
symptoms highly suspicious for a SARS-CoV-2 infection, 
including cough, fever, and/or a myalgia diagnosis, or was 
based on computed tomography (CT) of the chest accord-
ing to local protocols. This composite diagnostic criterion 
was applied to both head and neck patients and health care 
workers on the index operating team.
Data Collection and Follow-Up
REDCap was used to record all data through its web ap-
plication. Recorded demographic variables included the 
country and hospital of operation, age, sex, and American 
Society of Anesthesiologists (ASA) physical status clas-
sification. Cardiac comorbidity was reported with the 
Revised Cardiac Risk Index.23 Head and neck data in-
cluded the tumor subsite, neck metastasis management 
(elective or therapeutic), flap or other reconstruction, 
airway management, and location of postoperative care. 
The status of the clinical environment (hot vs cold) was 
recorded, and this reflected the relative mixing or separa-
tion of known or suspected COVID-19 admissions with 
oncology cases. Cold sites were defined as those hospitals 
that did not admit patients with COVID-19 or in which 
there was complete segregation of wards and operating 
and critical care environments. Hot sites were defined as 
those in which there was incomplete or no segregation 
of services. The magnitude of surgery was categorized24,25 
as minor (minor/intermediate) or major (major/complex 
major). Screening was defined as a preoperative SARS-
CoV-2 swab or CT scan in the 72 hours before surgery. 
The community SARS-CoV-2 incidence was categorized 
as low (<25 cases per 100,000) or high (≥25 cases per 
100,000) during February, March, and April 2020 and 
was derived from the relevant registries.26-28
Complications at 30 days were categorized with the 
Clavien-Dindo grade,29 and reconstructive outcomes 
were recorded. Before the locking of the data set for anal-
ysis, the senior local principal investigator for each hos-
pital was asked to confirm data completeness and that all 
eligible patients had been entered into the database.
Statistical Analysis
Continuous data were summarized as medians and in-
terquartile ranges, and categorical data were described as 
frequencies of counts and percentages. Proportions were 
compared with a 2-sided Fisher exact test, and a signifi-
cance level of 5% was used to determine statistical signifi-
cance. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were estimated with univariate logistic regression. 
All statistical analyses were performed with R version 
3.6.1. The detailed protocol is available at https://globa 
lsurg.org/cance rcovi dsurg/.
RESULTS
Patient Data
Data were collected for 1137 patients from 133 hospi-
tals in 26 countries who were undergoing primary sur-
gery with curative intent. The greatest numbers of cases 
were ascertained from the United Kingdom (350 patients 
[31%]), the United States (220 patients [19%]), Italy 
(165 patients [15%]), and Spain (84 patients [7%]). The 
number of cases per week was highest from March 16 to 
23 (188 surgeries).
Baseline Characteristics of the Patients
The baseline characteristics of the patients and tumors 
are shown in Table 1. Fifty-seven percent of the patients 
were male, and 62% were 60 years old or older. Thirty-
three percent of the patients had an ASA score ≥ 3, and 
11% had an Eastern Cooperative Oncology Group per-
formance status ≥ 2. Patients had T3/T4 tumors in 31% 
of cases and positive neck disease in 32%. OC was the 
commonest cancer site in 38% of cases (n = 433), and 
it was followed by the thyroid (21% [n = 235]) and cu-
taneous (14% [n = 157]). Notably, L and OP accounted 
for only 8% and 6%, respectively (87 and 73 cases). 
Subsequent analyses are presented with categorization 
into OC and non-OC groups. Seventy-eight percent of 
the hospital sites were categorized as hot, and 15% of the 
patients were in high SARS-CoV-2 incidence areas. Fifty-
one percent of the patients (579 of 1127) were screened 
for COVID-19 by laboratory tests or CT chest imaging. 
There was an equal split between major and minor sur-
gery. The commonest comorbidities were hypertension 
(40%), diabetes mellitus (14%), and respiratory problems 
(11%: chronic obstructive pulmonary disease [6%] and 
asthma [5%]; Table 2).
Surgery
Eighty-nine percent of the operations (1015 of 1137) 
included surgical excision of a primary tumor, and 50% 
(567 of 1137) included a neck dissection. The propor-
tions of patients with OC tumors undergoing neck 
dissection were as follows: T1, 30% (40 of 133); T2, 
74% (87 of 118); T3, 88% (44 of 50); T4, 83% (87 
of 105); and unknown T stage, 27 (total, 63% [271 of 
433]). This is less than would normally be expected and 
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indicates a significant de-escalation of neck manage-
ment. Thirty-one percent of the patients (355 of 1137) 
had reconstruction, but only around half of those re-
ceived free flaps requiring microvascular anastomosis 
(17% [191 of 1137]). Of the operations for OC tu-
mors, 52% (223 of 433) included some form of recon-
struction: a free flap in 33% (143 of 433), a local flap 
in 7% (32 of 433), a regional pedicled flap in 9% (39 of 
433), and obturation in 2% (8 of 433). In 13% of OC 
cases (57 of 433), surgeons stated that their reconstruc-
tive choice had been compromised in comparison with 
normal practice.
Airway Management
Airway management was extubation in 72% (822 of 
1137), tracheostomy in 17% (192 of 1137), and over-
night intubation in 3% (39 of 1137). Three percent (32 
of 1137) reported a change in airway technique in com-
parison with their normal practice, and this was mostly 
attributable to changes in airway management for 6% 
of OC tumors (26 of 433). Overall, 11% (120 of 1137) 
reported some change or compromise to their surgical 
management related to the effect of the COVID-19 pan-
demic, but this was approximately doubled for OC tu-
mors at 20% (80 of 433).
Postoperative Complications
The 30-day complications for 1130 patients are described 
in Table 3. The commonest complications were wound 
dehiscence/infection, which was seen in 11% (119 of 
1130), and pneumonia, which was seen in 4% (40 of 
1130). The 30-day postoperative mortality rate was 1.2% 
(14 of 1130). Among the 351 patients who underwent 
flap reconstruction and had 30-day outcomes, there were 
4 total flap failures (1%) and 14 partial failures (4%); 12 
patients had a viable reconstruction with a persistent fis-
tula (3%).
Incidence of Postoperative SARS-CoV-2/
COVID-19 and Severe Pulmonary Complications
A diagnosis of COVID-19 or a positive test for SARS-
CoV-2 was found for 29 of 1127 patients (3%) within 
30 days of surgery; 25 were laboratory diagnoses. Severe 
pulmonary complications attributed to COVID-19 oc-
curred in 13 patients (44.8% of the positive patients). 
For these 13 patients, the 30-day outcome was dis-
charge (n = 10) or death (n = 3). COVID-19–related 
deaths within 30 days of surgery occurred, therefore, 
in less than 0.3% of all operated patients but in 10.3% 
of those infected. Factors associated with severe pul-
monary complications in COVID-19–positive patients 
were determined by univariate analysis (Table 4 and 
Fig. 1). There were significant correlations with an ad-
vanced T stage (OR for T4, 11.5; 95% CI, 1.33-99.2), 
node-positive disease (OR for N2/3, 6.94; 95% CI, 
1.53-31.36), and admission to critical care (OR, 3.85; 
95% CI, 1.28-11.58). There were trends that did not 
reach statistical significance for patients undergoing 
surgery in hot surgical units (P = .084) and for pa-
tients who were screened for SARS-CoV-2 preopera-
tively (P = .092). Notably, there were not significant 
associations with age; ASA score; Eastern Cooperative 
Oncology Group performance status; Revised Cardiac 
Risk Index; tumor site; or any aspect of surgery, includ-
ing free-flap reconstruction, or airway management, in-
cluding tracheostomy.
COVID-19 Diagnosis in the Surgical Team
Members of the surgical team developed COVID-
19 within 30 days in 3.5% of operations (40 of 1130; 
Table 5 and Fig. 2). There was a significant association 
with operations in which the patient subsequently tested 
positive for SARS-CoV-2 within 30 days (OR, 10.3; 
95% CI, 4.1-25.8); remarkably, after 24% of the pro-
cedures in which a patient tested positive, a member of 
the head and neck surgical team developed COVID-19 
within 30 days. There were also associations with a high 
community SARS-CoV-2 incidence (OR, 4.0; 95% CI, 
2.1-7.7), with patients who had been screened for SARS-
CoV-2 preoperatively (OR, 2.9; 95% CI, 1.4-6.1), with 
TABLE 2. Baseline Comorbidities
Comorbidity
Oral  
(n = 433), 
No. (%)
Not Oral  
(n = 704),  
No. (%)
Total  
(n = 1137), 
No. (%)
Current smoker 106 (24) 95 (13) 201 (18)
Asthma 19 (4) 43 (6) 62 (5)
Chronic kidney 
disease
14 (3) 28 (4) 42 (4)
COPD 26 (6) 43 (6) 69 (6)
Congenital cardiac 
abnormality
1 (0) 4 (1) 5 (0)
Congestive heart 
failure
10 (2) 18 (3) 28 (2)
Dementia 6 (1) 7 (1) 13 (1)
Diabetes mellitus 60 (14) 95 (13) 155 (14)
Hypertension 180 (42) 271 (38) 451 (40)
Myocardial 
infarction
31 (7) 44 (6) 75 (7)
Peripheral vascular 
disease
17 (4) 26 (4) 43 (4)
Stroke/TIA 26 (6) 26 (4) 52 (5)
Other 182 (42) 265 (38) 447 (39)
Abbreviations: COPD, chronic obstructive pulmonary disease; TIA, transient 
ischemic attack.
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oral tumor site operations (OR, 5.3; 95% CI, 1.24-22.7), 
with the use of tracheostomy (OR, 2.6; 95% CI, 1.3-
5.1), and with surgical complication (OR, 3.5; 95% 
CI, 1.7-7.1). The data for the community incidence of 
COVID-19 typically showed 100 to 200 infections per 
100,000 population per month for high-risk regions in 
the period of case ascertainment. The frequency of infec-
tions that we have demonstrated in members of the surgi-
cal teams reflects an at least 1 order of magnitude higher 
risk than the community incidence, and this suggests that 
occupational exposure was the predominant mechanism.
DISCUSSION
These data allow a unique international perspective 
on the safety of head and neck cancer surgery during 
the COVID-19 pandemic and on changes in practice 
brought about in response to perceived risk. Although ob-
servational, the data reflect significant changes in practice 
arising from concerns about the perceived vulnerability 
of patients with cancer, cancelled surgery, and published 
guidelines. Although the first COVID-19 peak has passed 
in Europe and New York at the time of this writing, it is 
evident that Europe faces a significant second peak. These 
data have lasting international significance and will in-
form practice for future outbreaks and for other regions 
with a rising incidence of COVID-19.
There are several limitations to the methodology used 
that limit interpretation of the data. Regarding the case defi-
nition, these observational data take a pragmatic approach 
to the diagnosis of COVID-19 and reflect shifting standards 
and resources of hospitals and health systems and at the na-
tional level in the early months of this pandemic. Prospective 
interventional studies would doubtless involve a more rigor-
ous testing protocol to define COVID-19 cases. It is possible 
that undiagnosed SARS-CoV-2 infections or infections caus-
ing only minor symptoms may be underreported at the 30-
day endpoint. The data show some noteworthy associations 
but cannot be conclusive about causation and mechanism 
TABLE 3. 30-Day Complications and Outcomes
Oral (n = 427), 
No. (%)
Not Oral (n = 703), 
No. (%)
Total (n = 1130), 
No. (%)
Complication
Acute kidney injury 5 (1) 1 (0) 6 (1)
ARDS 2 (0) 1 (0) 3 (0)
Bleeding requiring transfusion 18 (4) 6 (1) 24 (2)
Cardiac arrest requiring CPR 3 (1) 2 (0) 5 (0)
Deep vein thrombosis 0 (0) 2 (0) 2 (0)
Graft/flap failure 12 (3) 1 (0) 13 (1)
Myocardial infarction 2 (0) 0 (0) 2 (0)
Pneumonia 21 (5) 19 (3) 40 (4)
Pulmonary embolism 0 (0) 2 (0) 2 (0)
Sepsis 3 (1) 4 (1) 7 (1)
Septic shock 1 (0) 1 (0) 2 (0)
Stroke 0 (0) 2 (0) 2 (0)
Urinary tract infection 4 (1) 2 (0) 6 (1)
Wound sepsis or dehiscence 74 (17) 45 (6) 119 (11)
Other complication 69 (16) 91 (13) 160 (14)
30-d outcomes
Alive: discharged home 404 (95) 681 (97) 1085 (96)
Alive: discharged to a rehabilitation center 2 (0) 4 (1) 6 (1)
Alive: remained admitted to hospital 11 (3) 13 (2) 24 (2)
Alive: transferred to another hospital 1 (0) 0 (0) 1 (0)
Died 9 (2.1) 5 (1) 14 (1.2)
Highest Clavien-Dindo grade as inpatient up to 30 da
None 314 (74) 557 (79) 871 (77)
Grade 1: deviation from postoperative course without pharmaceutical intervention 16 (4) 60 (9) 76 (7)
Grade 2: pharmaceutical intervention only 42 (10) 56 (8) 98 (9)
Grade 3A: surgical, endoscopic, or radiological reintervention (not under general 
anesthetic)
19 (4) 13 (2) 32 (3)
Grade 3B: surgical, endoscopic, or radiological reintervention (under general 
anesthetic)
23 (5) 10 (1) 33 (3)
Grade 4A: life-threatening complication requiring intensive care management 
(single-organ dysfunction)
5 (1) 4 (1) 9 (1)
Grade 4B : life-threatening complication requiring intensive care management 
(multiple-organ dysfunction)
1 (0) 1 (0) 2 (0)
Unknown 2 (0) 1 (0) 3 (0)
Abbreviations: ARDS, acute respiratory distress syndrome; CPR, cardiopulmonary resuscitation.
aClavien-Dindo grade 5 is death; it is reported under 30-day outcomes.
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(particularly the direction of cross-infection or whether 
patients were infected pre-, peri-, or postoperatively). Finally, 
the data reflecting changes in, or the avoidance of, surgery 
can be only best estimates against historical data.
Case ascertainment aligns well with global geographic 
regions experiencing the highest incidence of COVID-
19 during this period; the United Kingdom, Italy, Spain, 
and New York City were particularly well represented. 
TABLE 4. Univariate Correlations Between Severe Pulmonary Complications of COVID-19 and Patient, 
Operation, and Hospital Characteristics
Covariate Value
Severe COVID-19 Pulmonary 
Complication, No. (%)
Total, No. P-valueNo Yes
Age <40 y 95 (99) 1 (1) 96 .829
40-69 y 650 (99) 9 (1) 659
≥70 y 372 (99) 3 (1) 375
Sex Female 475 (99) 5 (1) 480 1
Male 639 (99) 8 (1) 647
ASA grade 1 or 2 751 (99) 7 (1) 758 .374
3 or 4 365 (98) 6 (2) 371
ECOG/WHO PS 0/1 983 (99) 11 (1) 994 .656
≥2 129 (98) 2 (2) 131
Smoker No 919 (99) 11 (1) 930 1
Yes 198 (99) 2 (1) 200
Tumor subsite Larynx, hypo/oropharynx 171 (99) 1 (1) 172 .903
Oral 421 (99) 6 (1) 427
Other 294 (99) 3 (1) 297
Thyroid 231 (99) 3 (1) 234
Reconstruction Free flap 185 (98) 4 (2) 189 .69
Other reconstruction 162 (99) 2 (1) 164
Airway management Extubation at completion of 
procedure
810 (99) 7 (1) 817 .202
Other 118 (98) 2 (2) 120
Tracheostomy 188 (98) 4 (2) 192
Care in ITU from theater No 912 (99) 7 (1) 919 .02
Yes 203 (97) 6 (3) 209
Clinical T stage T1 361 (100) 1 (0) 362 .037
T2 274 (99) 3 (1) 277
T3 123 (98) 2 (2) 125
T4 157 (97) 5 (3) 162
Clinical N stage N0 671 (100) 3 (0) 674 .004
N1 184 (97) 5 (3) 189
N2/3 129 (97) 4 (3) 133
Clinical M stage M0 898 (99) 10 (1) 908 1
M1 10 (100) 0 (0) 10
General anesthetic No 76 (99) 1 (1) 77 .602
Yes 1041 (99) 12 (1) 1053
Screened preoperatively No 546 (99) 3 (1) 549 .092
Yes 571 (98) 10 (2) 581
Surgical complicationsa No 1001 (99) 10 (1) 1011 .149
Yes 116 (97) 3 (3) 119
Grade of surgery Major 552 (99) 8 (1) 560 .418
Minor 563 (99) 5 (1) 568
Community SARS-CoV-2 incidence High 169 (98) 3 (2) 172 .432
Low 948 (99) 10 (1) 958
RCRI 0 852 (99) 10 (1) 862 .671
1 201 (99) 2 (1) 203
2 50 (98) 1 (2) 51
≥3 14 (100) 0 (0) 14
Hot vs cold unit Cold 250 (100) 0 (0) 250 .084
Hot 867 (99) 13 (1) 880
Abbreviations: ASA, American Society of Anesthesiologists; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; ITU, intensive 
therapy unit; PS, performance status; RCRI, Revised Cardiac Risk Index; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health 
Organization.
P
A severe pulmonary complication of COVID-19 was defined as a diagnosis of COVID-19 or a SARS-CoV-2–positive test and pneumonia, acute respiratory distress 
syndrome, or a pulmonary embolism.
aA surgical complication was defined as either a deep or superficial wound infection or wound dehiscence.
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Figure 1. Forest plot of associations with severe pulmonary complications of COVID-19 in patients. ASA indicates American Society 
of Anesthesiologists; CI, confidence interval; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; 
H&N, head and neck; ITU, intensive therapy unit; NE, not evaluable; PS, performance status; RCRI, Revised Cardiac Risk Index; SARS-
CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
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Postoperative COVID-19/SARS-CoV-2 and severe pul-
monary complications were seen in 3% and 1% of patients, 
respectively. The overall 30-day postoperative mortality 
rate was 1.2%, which is similar to pre-COVID data.30,31 
Patients were more likely to develop severe pulmonary com-
plications of COVID-19 if they had an advanced tumor 
stage or if they had been admitted to critical care. However, 
the absolute risks were approximately 3%, and this should 
TABLE 5. Univariate Correlations Between COVID-19 Developing in a Member of the Surgical Team Within 
30 Days and Patient, Operation, and Hospital Characteristics
Covariate Value
Member of Surgical Team Diagnosed With 
COVID-19 Within 30 d, No. (%)
Total, No. PNo Yes
Age <40 y 91 (97) 3 (3) 94 1
40-69 y 635 (96) 24 (4) 659
≥70 y 361 (97) 13 (3) 374
Sex Female 463 (97) 16 (3) 479 .871
Male 621 (96) 24 (4) 645
ASA grade 1 or 2 726 (96) 31 (4) 757 .174
3 or 4 360 (98) 9 (2) 369
ECOG/WHO PS 0/1 956 (96) 36 (4) 992 1
≥2 127 (97) 4 (3) 131
Smoker No 899 (97) 30 (3) 929 .207
Yes 188 (95) 10 (5) 198
Tumor subsite Larynx, hypo/oropharynx 170 (99) 2 (1) 172 <.001
Oral 400 (94) 25 (6) 425
Other 295 (99) 2 (1) 297
Thyroid 222 (95) 11 (5) 233
Reconstruction Free flap 176 (94) 12 (6) 188 .823
Other 154 (94) 9 (6) 163
Airway management Extubation 791 (97) 24 (3) 815 .012
Other 118 (98) 2 (2) 120
Tracheostomy 177 (93) 14 (7) 191
Care in ITU from theater No 887 (97) 31 (3) 918 .533
Yes 199 (96) 9 (4) 208
Clinical T stage T1 345 (96) 16 (4) 361 .285
T2 269 (97) 8 (3) 277
T3 120 (96) 5 (4) 125
T4 150 (93) 11 (7) 161
Clinical N stage N0 646 (96) 27 (4) 673 .2
N1 185 (98) 4 (2) 189
N2/3 124 (94) 8 (6) 132
Clinical M stage M0 869 (96) 37 (4) 906 1
M1 10 (100) 0 (0) 10
General anesthetic No 77 (100) 0 (0) 77 .106
Yes 1010 (96) 40 (4) 1050
Screened preoperatively No 538 (98) 10 (2) 548 .003
Yes 549 (95) 30 (5) 579
Patient positive for SARS-Cov-2/
COVID-19a
No 1065 (97) 33 (3) 1098 <.001
Yes 22 (76) 7 (24) 29
Hot vs cold unit Cold 245 (98) 5 (2) 250 .174
Hot 842 (96) 35 (4) 877
Surgical complicationsb No 980 (97) 29 (3) 1009 .002
Yes 107 (91) 11 (9) 118
Grade of surgery Major 533 (96) 24 (4) 557 .199
Minor 552 (97) 16 (3) 568
Community SARS-CoV-2 incidence Low 931 (97) 24 (3) 955 <.001
Moderate or high 156 (91) 16 (9) 172
RCRI 0 831 (97) 30 (3) 861 .837
1 192 (96) 9 (4) 201
2 50 (98) 1 (2) 51
≥3 14 (100) 0 (0) 14
Abbreviations: ASA, American Society of Anesthesiologists; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; ITU, intensive 
therapy unit; PS, performance status; RCRI, Revised Cardiac Risk Index; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health 
Organization.
P-values in bold are <.05, statistically significant, and in italics are between .05 and <.1.
aPositivity for SARS-Cov-2/COVID-19 was defined as a diagnosis of COVID-19 or a SARS-CoV-2–positive test and pneumonia, acute respiratory distress syn-
drome, or a pulmonary embolism.
bA surgical complication was defined as either a deep or superficial wound infection or wound dehiscence.
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Figure 2. Forest plot of associations with the diagnosis of COVID-19 in members of the surgical team. ASA indicates American 
Society of Anesthesiologists; CI, confidence interval; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology 
Group; H&N, head and neck; ITU, intensive therapy unit; NE, not evaluable; PS, performance status; RCRI, Revised Cardiac Risk Index; 
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
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be considered from the perspective of the dismal prognosis 
for these patients if appropriate cancer treatment had been 
withheld. The rates of severe respiratory complications and 
mortality among those developing postoperative COVID-
19 were 44% (13 of 29) and 10.3% (3 of 29), respectively. 
It is speculated that these might have been avoided by the 
uniform adoption of patient segregation, screening, and 
use of personal protective equipment (PPE). There were 
nonsignificant trends toward higher patient risk if surgery 
was performed in hot units and in areas with a higher com-
munity SARS-CoV-2 incidence, although it is recognized 
that such dichotomization of risk is imprecise. Many head 
and neck surgery teams could not relocate to cold sites 
because of their requirement for specialist skills and other 
equipment. It is reassuring that even for high-risk areas 
and hot units, the risk of severe COVID-19 pulmonary 
complications was relatively modest. Medical and surgical 
complications were within the ranges normally seen for the 
cohort as a whole. Head and neck surgery was safe for pa-
tients, and it was noteworthy that this safety extended to 
surgeries that were prolonged, involved complex surgery, or 
involved free-flap reconstruction.
It is particularly concerning that 40 members of the 
surgical teams developed COVID-19 within 30 days of 
surgery within this cohort. In 24% of the operations in 
which the patient developed COVID-19 or tested pos-
itive for SARS-Cov-2, a member of the operating team 
later developed COVID-19. This high incidence of in-
fection cannot be easily attributed merely to community 
transmission because even for regions of high community 
transmission, the risk to members of the surgical team 
was typically an order of magnitude higher than this 
background rate. The outcome of these surgeons’ illnesses 
has not been sought in this study, nor have the details of 
the PPE used or the additional clinical roles performed 
for inpatients with COVID-19 in the same period. It is 
not possible to clarify a mechanism or direction of trans-
mission; this is at least circumstantial evidence of some 
deficiency in the adoption or application of PPE. These 
data are unique and confirm previously expressed con-
cerns that head and neck cancer surgical teams are vul-
nerable, potentially highly so, to acquiring COVID-19 
during aerosol-generating procedures.
The distribution of cases operated by site was oral 
cavity (OC) 38%, larynx (L) 8% and oropharynx (OP) 
6%. Within countries submitting the majority of cases, the 
distribution of cases by anatomical site differs significantly 
from the predicted incidence, most notably for L and OP. 
The analysis of these data is imprecise because it relies 
on historical comparisons, but estimates of therapeutic 
migration away from surgery to radiotherapy-based pro-
tocols are possible. The Global Cancer Observatory indi-
cates that OC accounts for 45% of squamous carcinomas 
worldwide (the United Kingdom, 58%; the United States, 
49%; and Spain, 50%). OP accounts for 12% (the United 
Kingdom, 29%; the United States, 25%; and Spain, 13%), 
and L accounts for 22% (the United Kingdom, 24%; the 
United States, 11%; and Spain, 30%).32 The low inclusion 
of L and OP cases receiving primary surgery reported here 
suggests a significant change in the treatment pathway in 
comparison with historical data from the United Kingdom, 
the United States, and Europe. Among UK patients hav-
ing major head and neck surgery in 2004-2009, 70% of 
OC cancers, 35% of OP cancers, and 43% of L cancers 
were treated with primary surgery.33 Data from 2013-2015 
(OC, 76%; OP, 43%; and L, 45%)34 and 2016 (OC, 75%; 
OP, 35%; and L, 48%)35 were similar. In the United States, 
2009 data from the Surveillance, Epidemiology, and End 
Results database showed that 82% of OC cancers, 28% 
of OP cancers, and 32% of L cancers were treated with 
primary surgery.36 An analysis of National Cancer Data 
Base figures from 2004 to 2013 shows that for T1/T2 OP 
cancers, the rate of primary surgery rose from 56% in 2004 
to 82% in 2013.37 In Spain, data from Madrid illustrate 
that in 2017, 74% of OC cancers, 34% of OP cancers, and 
71% of L cancers were treated with surgery.38 Data from 
the Netherlands Cancer Registry in 2008 are similar (OC, 
88%; OP, 27%; and L, 28%).39
There are several explanations for the observed 
changes in the proportions of patients undergoing surgery. 
It is possible that specific cohorts of patients may not have 
been presented; however, the preservation of OC cases 
treated with surgery makes this less likely. It is more prob-
able that the treatment modality may have changed. It has 
been estimated that 37% of cancer surgeries have been can-
celled during the COVID-19 pandemic.1 It is, therefore, 
probable that patients amenable to surgery were treated at a 
higher rate with primary radiotherapy or chemoradiother-
apy instead. This may be due to the perceived risk of sur-
gery for patients and health care workers or due to a lack of 
capacity. It is unclear what impact this will have on cancer 
outcomes or if there will be any increased risks of COVID-
19 for those receiving chemoradiotherapy, and longer fol-
low-up for this cohort may clarify these potential risks.
Primary surgery is a standard of care for OC malig-
nancies and usually extends to surgical neck staging be-
cause occult metastases are very common. Neck dissection 
was omitted in 70% of T1 cases, 26% of T2 cases, 12% 
of T3 cases, and 17% of T4 cases (37% overall). Nine 
percent of the cases for which neck dissection was omitted 
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had clinical or radiologically evident nodal metastases 
(cN1-3); therefore, the management of the clinically N0 
neck was substantially more conservative in comparison 
with historical norms of 19% to 28% for all-stage oral 
cancer series,40,41 and this may have significant oncologi-
cal consequences.42,43 The use of reconstruction and free-
flap microvascular reconstruction also appears to be less 
frequent than historical norms. In this cohort, 45% of 
oral cancer cases had some form of reconstruction, and 
the 74 free flaps represented only 25% of these cases. 
These data indicate fewer patients receiving free flaps in 
comparison with other recent series40 and greater reliance 
on more basic techniques that avoid microsurgery to offer 
simpler and shorter operations.
The presented data support the idea that head 
and neck cancer surgery can be executed safely even in 
high-incidence communities. This safety extends to more 
complex and prolonged procedures, including those re-
quiring free-flap reconstruction. The rate of severe pul-
monary complications of COVID-19, although not high, 
might yet be reduced by rigorous screening, demarcation 
of hot and cold inpatient sites, regular staff testing, and 
effective PPE. Notwithstanding the low rate of infection, 
the consequences for affected patients were high rates of 
serious pulmonary complications and mortality. There 
was a concerning overlap in COVID-19 between patients 
and their surgeons; one explanation would be some fail-
ure of cross-infection measures. Along with early data on 
the safety of chemotherapy,44 it appears that with some 
mitigations, standard cancer therapy for head and neck 
cancers need not be withheld during the COVID-19 pan-
demic even in high-incidence regions.
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